Salman Bin Mahmood
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Salman Bin Mahmood has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Fariha Hasan
Department of Microbiology, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad 45320, Pakistan
1 shared publication - Javaid Ahmed Khan
Section of Pulmonology and Critical Care, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan
1 shared publication - Manesh Kumar Gangwani
Department of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
1 shared publication Yi Peng
Chronic Disease Research Group Hennepin Healthcare Research Institute Minneapolis MN USA
1 shared publicationYuanyuan Ji
Chronic Disease Research Group Hennepin Healthcare Research Institute Minneapolis MN USA
1 shared publication- Zaki Abou Zahr
Division of Rheumatology Minneapolis MN USA
1 shared publication
Latest Publications
- 5 November 2020
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 24 (1) , 63-68
Incidence of giant cell arteritis after bisphosphonate exposure: A retrospective cohort study
Objectives Bisphosphonates may cause autoimmune reactions via a cytokine‐mediated acute phase response. A case of giant cell arteritis (GCA) after zoledronate injection was recently reported. We aimed to evaluate this association by reviewing the incidence of GCA after bisphosphonate administration. Methods This was a retrospective study using the medical claims data of elderly patients in the 20% Medicare random sample from 2008‐2014 who had received zoledronate or ibandronate. Patients who had a diagnosis claim of GCA within the past year before receiving either bisphosphonate were excluded. The development of GCA was assessed in 2 ways: GCA diagnosis claim within 28 days of bisphosphonate injection and another claim within 90 days of initial claim; and temporal artery biopsy claim within 28 days of bisphosphonate injection and GCA diagnosis claim within 90 days of biopsy. Due to the Centers for Medicare & Medicaid Services reporting requirements we excluded numbers less than 11 from analysis. Results The incidence of GCA was 0.010% and 0.013% after zoledronate and ibandronate injection respectively. In the zoledronate group incidence was highest in patients aged 75‐85 years (0.011%), in Whites (0.011%), in the northeast census region (0.013%) and higher in females (0.011% vs 0.009%). All GCA cases noted in the ibandronate group involved White females. We are unable to report incidences by age and region due to the paucity of data. Conclusion The incidence of GCA after bisphosphonate injection was not increased compared to the generally reported incidence in the USA.
- 5 November 2020
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 24 (1) , 63-68
Incidence of giant cell arteritis after bisphosphonate exposure: A retrospective cohort study
Objectives Bisphosphonates may cause autoimmune reactions via a cytokine‐mediated acute phase response. A case of giant cell arteritis (GCA) after zoledronate injection was recently reported. We aimed to evaluate this association by reviewing the incidence of GCA after bisphosphonate administration. Methods This was a retrospective study using the medical claims data of elderly patients in the 20% Medicare random sample from 2008‐2014 who had received zoledronate or ibandronate. Patients who had a diagnosis claim of GCA within the past year before receiving either bisphosphonate were excluded. The development of GCA was assessed in 2 ways: GCA diagnosis claim within 28 days of bisphosphonate injection and another claim within 90 days of initial claim; and temporal artery biopsy claim within 28 days of bisphosphonate injection and GCA diagnosis claim within 90 days of biopsy. Due to the Centers for Medicare & Medicaid Services reporting requirements we excluded numbers less than 11 from analysis. Results The incidence of GCA was 0.010% and 0.013% after zoledronate and ibandronate injection respectively. In the zoledronate group incidence was highest in patients aged 75‐85 years (0.011%), in Whites (0.011%), in the northeast census region (0.013%) and higher in females (0.011% vs 0.009%). All GCA cases noted in the ibandronate group involved White females. We are unable to report incidences by age and region due to the paucity of data. Conclusion The incidence of GCA after bisphosphonate injection was not increased compared to the generally reported incidence in the USA.
- Open Access
- 9 April 2018
- Published by Springer Nature in Cureus
- Vol. 10 (4) , e2451
Constrictive Pericarditis Presenting as Bilateral Pleural Effusion: A Report of Two Cases
Constrictive pericarditis is a rare presentation. We need a very high index of clinical suspicion to diagnose the disease. It most commonly presents secondary to tuberculosis (TB) in the developing world and post-radiation therapy in the developed world. Classically, it presents with symptoms of heart failure and as pericardial thickening or calcification on imaging studies. In hospital settings, constrictive pericarditis is not usually considered as a differential in patients presenting with pleural effusion. According to the literature, associated pleural effusions in cases of constrictive pericarditis could be left-sided. Herein, we present two unusual presentations of cases with bilateral pleural effusions. One of our cases developed constrictive pericarditis with concurrent active tuberculosis. This is a rare presentation because, normally, constrictive pericarditis is a late complication of tuberculosis. We suggest that when dealing with cases of bilateral pleural effusion, the etiology of constrictive pericarditis should be considered.
- 9 April 2018
- Published by Springer Nature in Cureus
- Vol. 10 (4) , e2451
Open AccessConstrictive Pericarditis Presenting as Bilateral Pleural Effusion: A Report of Two Cases
Constrictive pericarditis is a rare presentation. We need a very high index of clinical suspicion to diagnose the disease. It most commonly presents secondary to tuberculosis (TB) in the developing world and post-radiation therapy in the developed world. Classically, it presents with symptoms of heart failure and as pericardial thickening or calcification on imaging studies. In hospital settings, constrictive pericarditis is not usually considered as a differential in patients presenting with pleural effusion. According to the literature, associated pleural effusions in cases of constrictive pericarditis could be left-sided. Herein, we present two unusual presentations of cases with bilateral pleural effusions. One of our cases developed constrictive pericarditis with concurrent active tuberculosis. This is a rare presentation because, normally, constrictive pericarditis is a late complication of tuberculosis. We suggest that when dealing with cases of bilateral pleural effusion, the etiology of constrictive pericarditis should be considered.